Role of thigh circumference, calf circumference, subjective global assessment, and handgrip strength as diagnostic modalities of sarcopenia in women inflammatory bowel disease patients

Rabbino Rangga Pribadi, * Marcellus Simadibrata, * Andri Sanityoso Sulaiman† and Mardani Abdullah *

Division of *Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia and †Hepatobiliary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia

Key words
calf circumference, cutoff point, diagnostic accuracy, handgrip strength, inflammatory bowel disease, sarcopenia, subjective global assessment, thigh circumference.

Accepted for publication 11 July 2022.

Correspondence
Rabbino Rangga Pribadi, Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jl. Diponegoro no. 71, Jakarta 14310, Indonesia.
Email: rabbinurangga@gmail.com

Declaration of conflict of interest: The authors declare no conflict of interest.

Abstract

Background and Aim: Sarcopenia is a problem affecting inflammatory bowel disease (IBD) outcome and should be evaluated by measuring muscle mass (using dual-energy X-ray absorptiometry [DXA]), muscle strength, and physical performance. DXA has drawbacks as it is expensive, not covered by a national program, and requires a technician. Other inexpensive and simple examinations are needed. The objective is to explore cutoff point and diagnostic accuracy of thigh circumference (TC), calf circumference (CC), subjective global assessment (SGA), and handgrip strength (HGS) to identify sarcopenia in IBD patients.

Methods: The study was conducted in Cipto Mangunkusumo Hospital during November 2020–June 2021. Analysis was performed to discover the cutoff point and diagnostic accuracy of TC, CC, SGA, and HGS to identify sarcopenia.

Results: As assessed by DXA, 7 of 60 women (11.7%) with IBD had sarcopenia. Using CC cutoff ≤31 cm, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were 100%, 60.38%, 25%, 100%, 2.52, and 0, respectively. Using TC cutoff ≤50 cm, the sensitivity, specificity, PPV, NPV, PLR, and NLR were 100%, 83.02%, 43.75%, 100%, 5.90, and 0, respectively. SGAs has sensitivity, specificity, PPV, NPV, PLR, and NLR of 42.86%, 84.91%, 27.27%, 91.84%, 2.84, and 0.67, respectively. The area under curve of HGS was 33.3%.

Conclusion: In this survey of Indonesian women with IBD, the frequency of sarcopenia was 11.7%. When compared with DXA, TC and CC values over 50 cm and 31 cm, respectively, were helpful to exclude the diagnosis of sarcopenia. SGA and HGS were of lesser value for the identification of a decrease in muscle mass.

Introduction

Inflammatory bowel disease (IBD) is a chronic bowel inflammation that consists of two subtypes, ulcerative colitis (UC) and Crohn’s disease (CD). It is related to a significant increase in mortality, morbidity, and cost.¹–³ Bewtra et al.⁴ showed that all-cause standardized mortality ratio (SMR) was 1.19 in UC and 1.38 in CD. Patients frequently have fatigue, depression, anxiety, and sleep disturbance, which affect their quality of life.⁵ The IBD cost of care was also three times higher compared with non-IBD patients (US $ 22 987 vs 6956).⁶

One main issue that affects IBD outcome is sarcopenia.⁷–⁹ According to the Asian Working Group of Sarcopenia (AWGS), sarcopenia is decrease of muscle mass with decreased muscle strength and/or physical performance.¹⁰ A systematic review by Ryan et al.¹¹ revealed that the prevalence of sarcopenia is 42% in IBD patients. Sarcopenia affects IBD outcome, as it is related to increased risk of post-surgery complications, and faster time of biologic agent failure.¹²

Sarcopenia has considerable impact on IBD outcome and therefore should be evaluated in all IBD patients. Sarcopenia evaluation comprises measuring muscle mass (using the gold standard dual-energy X-ray absorptiometry [DXA]), muscle strength (using Jamar dynamometer to measure handgrip strength [HGS]), and physical performance (using five times chair stand test).⁸ Although DXA is of utmost importance, it has several drawbacks as it is expensive and not covered by the national insurance program, and it requires a skilled technician. Those
disadvantages should be addressed by evaluating other inexpensive and simple alternative examinations, for example, thigh circumference (TC), calf circumference (CC), subjective global assessment (SGA), and HGS.

The diagnostic accuracy of TC and CC had been studied by Mitayani et al.13 in geriatric population. Using women CC cutoff point of 29 cm, they revealed a 37% prevalence of sarcopenia with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of 71.4%, 95.5%, 62.5%, 97%, 15.87, and 0.3, respectively. Mienche et al.14 showed that by using women TC cutoff point 44 cm, the sensitivity, specificity, PPV, NPV, PLR, and NLR were 85.7%, 94%, 60%, 98.4%, 14.28, and 0.15, respectively.

SGA also has the potential to identify sarcopenia, yet its diagnostic accuracy is not known in IBD patients.15 In gastrointestinal patients (including IBD), Onishi et al.16 revealed that SGA has sensitivity, specificity, PPV, NPV, PLR, and NLR of 19.05%, 84%, 25%, 78.75%, 1.19, and 0.96. Another tool such as HGS showed a moderate positive correlation with muscle mass in gastrointestinal cancer patients.17 Cutoff point and diagnostic accuracy of TC, CC, SGA, and HGS had been studied among all subjects.

In gastroin-testinal patients (including IBD), Onishi et al.16 revealed that SGA has sensitivity, specificity, PPV, NPV, PLR, and NLR of 19.05%, 84%, 25%, 78.75%, 1.19, and 0.96. Another tool such as HGS showed a moderate positive correlation with muscle mass in gastrointestinal cancer patients.17 Cutoff point and diagnostic accuracy of TC, CC, SGA, and HGS had been studied among all subjects.

In women IBD patients, the area under curve (AUC) of CC was 82.5% (95% confidence interval [CI] 69.2–5.7) with P value = 0.006. The optimal cutoff point of CC was 31 cm, and it generates sensitivity, specificity, PPV, NPV, PLR, and NLR of 100%, 60.38%, 25%, 100%, 2.52, and 0. The AUC of CC is depicted in Figure 1.

In women IBD patient, the AUC of TC was 91.4% (95% CI 84.2–98.6%) with P value < 0.001. The optimal cutoff point of TC was 50 cm. From the current cutoff point, it generates sensitivity, specificity, PPV, NPV, PLR, and NLR of 100%, 83.02%, 43.75%, 100%, 5.89, and 0. The AUC of TC is depicted in Figure 2.

In women IBD patient, the diagnostic accuracy of SGA to identify sarcopenia is as follows: sensitivity is 42.86%; specificity is 84.91%; PPV is 27.27%; NPV is 91.84%; PLR is 2.84; and NLR is 0.67. The AUC of HGS to identify decrease of muscle mass was 33.3% (95% CI 18.9–47.8), P = 0.067 in women IBD patient group. Cutoff points and diagnostic accuracy of HGS were not explored further.

**Discussion**

Our study used AWGS 2019 criteria as the reference standard in diagnosing sarcopenia in IBD patients. The criteria are usually applied to geriatric population. It is not generally used in IBD patients; however, it is currently the best diagnostic criterion for sarcopenia in Asian population.

The AUC of CC is 82.5% (95% CI 69.2–95.7), P value = 0.006. If CC is performed on women IBD patients in clinical practice, it will measure precisely in 82 of 100 patients.
If CC is measured repeatedly in 100 patients in population, the correct value will be obtained in 69–95 patients. In a group of women IBD patients, the AUC of TC is 91.4% (95% CI 84.2–98.6), $P$ value $< 0.001$. If TC is measured repeatedly in 100 patients in population, the correct value will be obtained in 84–98 patients. Statistically, the AUC of TC is more accurate compared with CC.

Cutoff point for CC and TC was 31 and 50 cm. Using CC cutoff ≤31 cm, the sensitivity, specificity, PPV, NPV, PLR, NLR were 100%, 60.38%, 25%, 100%, 2.52, and 0. Using TC cutoff ≤50 cm, the sensitivity, specificity, PPV, NPV, PLR, and NLR were 100%, 83.02%, 43.75%, 100%, 5.90, and 0. Overall, the diagnostic accuracy of TC is higher than CC (83.02% vs 60.38%). The NPV and NLR of both TC and CC are very good (100% and 0), with PPV of TC being slightly higher than CC (43.75% vs 25%). From the comparison, it is decided that TC is the parameter that can be utilized in clinical practice to exclude sarcopenia in women IBD patients. The TC cutoff of 144 cm from previous research (Mienchef et al.) was not used in this study because it was applied in ambulatory geriatric patients. While our subjects were IBD women patients less than 60 years old whose muscle mass and/or function differ from geriatric patients.

The sensitivity, specificity, PPV, NPV, PLR, and NLR of SGA for identifying sarcopenia in women IBD patients were 42.86%, 84.91%, 27.27%, 91.84%, 2.84, and 0.67. The specificity is good, but the sensitivity, NPV, PLR, and NLR are not accurate enough. The NPV is good for excluding sarcopenia, but SGA is not as simple as CC or TC, and therefore it is not a preferable tool to exclude sarcopenia in women IBD patients. The HGS has an AUC of 33.3% in detecting low muscle mass in women IBD patients. Due to its low AUC, HGS cutoff point and diagnostic accuracy of HGS are not analyzed.

Our study has limitations. The diagnostic accuracy and new cutoff point cannot be applied to IBD women geriatric patients. As for the external validity and generalizability, the result of the study is not yet applicable for IBD women patients outside Cipto Mangunkusumo National General Hospital due to possible difference in disease severity compared with other healthcare facilities.

In conclusion, the optimal cutoff point of TC and CC is 50 and 31 cm, respectively. The diagnostic accuracy of both TC and CC is very good to exclude sarcopenia in female IBD patients. SGA is not accurate enough to exclude nor diagnose sarcopenia in female IBD patients. HGS is not accurate enough to identify the decrease of muscle mass in female IBD patients.

Acknowledgments

The authors would like to extend sincere gratitude to Gunawan Tirtarahardja, MD for his excellent expertise. The authors would like to thank Oemar Ichsan, MD, Eka Benhardi Layadi, MD, Megawati Ananda Hasbi Putri, MD, Muhammad IQbal, MD, and Bastomy Eka Rezkita, MD for their great assistance.

References

1. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin. Proc. 2019; 94: 155–65.
2. Kassam Z, Belga S, Roifman I et al. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm. Bowel Dis. 2014; 20: 2483–92.
3. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017; 390: 2769–78.
4. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm. Bowel Dis. 2013; 19: 599–613.
5. Radford SJ, McGing J, Cruber-Dochan W, Moran G. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterol. 2020; 12: 11–21.
6. Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm. Bowel Dis. 2020; 26: 1–10.
7. Hollingworth TW, Oke SM, Patel H, Smith TR. Getting to grips with sarcopenia: recent advances and practical management for the gastroenterologist. Frontline Gastroenterol. 2020; 101: 53–61.
8. Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 2019; 25: 67–73.
9. Pizzoferato M, de Sire R, Ingervalle F et al. Characterization of sarcopenia in an IBD population attending an Italian Gastroenterology Tertiary Center. Nutrients. 2019; 11: 2281.
10. Chen L-K, Woo J, Assantachai P et al. Asian Working Group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 2020; 21: 300–7.
11. Pedersen M, Cromwell J, Nau P. Sarcopenia is a predictor of surgical morbidity in inflammatory bowel disease. Inflamm. Bowel Dis. 2017; 23: 1867–72.
12 Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT. Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. *Eur. J. Clin. Nutr.* 2017; 71: 773–7.

13 Mitayani SH. Peran Lingkar Betis sebagai Prediktor Massa Otot pada Penegakkan Diagnosis Sarkopenia [Thesis]. Univ Indones, 2018.

14 Mienche M, Setiati S, Setyohadi B et al. Diagnostic performance of calf circumference, thigh circumference, and SARC-F questionnaire to identify sarcopenia in elderly compared to Asian Working Group for Sarcopenia’s Diagnostic Standard. *Acta Med. Indones.* 2019; 51: 117–27.

15 Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. *Gastroenterol Res Pract.* 2017; 2017: 1–11.

16 Onishi S, Shiraki M, Nishimura K, Hanai T, Moriwaki H, Shimizu M. Prevalence of sarcopenia and its relationship with nutritional state and quality of life in patients with digestive diseases. *J Nutr Sci Vitaminol (Tokyo).* 2018; 64: 445–53.

17 Moreau J, Ordan M, Barbe C, et al. Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. *Cancer Med.* 2019; 8: 3677–84.